Ionis Pharmaceuticals spinout Akcea Therapeutics will receive $50m from strategic partner Novartis as part of the offering.
Akcea Therapeutics, a US-based cardiometabolic disease-focused spinout of biopharmaceutical company Ionis Pharmaceuticals, yesterday filed to raise up to $100m in an initial public offering.
Founded in 2015, Akcea is working on therapies based on antisense technology developed by Ionis, to treat serious cardiometabolic diseases caused by lipid disorders.
The company’s lead drug candidate, volanesorsen, has completed a phase 3 clinical trial for familial chylomicronemia syndrome and is currently in a phase 3 trial for familial partial lipodystrophy.
Pharmaceutical firm…
